• 1
    Savage CO, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997; 349: 5538.
  • 2
    Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337: 151223.
  • 3
    Fahey J, Leonard E, Churg J, Godman GC. Wegener's granulomatosis. Am J Med 1954; 17: 16879.
  • 4
    Wegener F. Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol Anat Allg Pathol 1939; 102: 3668.
  • 5
    De Remee RA, McDonald TJ, Harrison EG Jr, Coles DT. Wegener's granulomatosis: anatomic correlates, a proposed classification. Mayo Clin Proc 1976; 51: 77781.
  • 6
    Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 7685.
  • 7
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 48898.
  • 8
    Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971; 285: 14936.
  • 9
    Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971; 284: 93842.
  • 10
    Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 60813.
  • 11
    de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 205261.
  • 12
    Krafcik SS, Covin RB, Lynch JP 3rd, Sitrin RG. Wegener's granulomatosis in the elderly. Chest 1996; 109: 4307.
  • 13
    Lê Thi Huong Du, Wechsler B, Cabane J, Piette JC, Herreman G, Guillevin L, et al. Wegener's granulomatosis: clinical aspects, nosologic problems: review of the literature a propos of 30 cases [in French]. Ann Med Interne (Paris) 1988; 139: 16982.
  • 14
    Vassallo M, Shepherd RJ, Iqbal P, Feehally I. Age-related variations in presentation and outcome in Wegener's granulomatosis. J R Coll Physicians Lond 1997; 31: 396400.
  • 15
    Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 102132.
  • 16
    Fauchais AL, Michon-Pasturel M, Rugale C, Asseray N, Bulckaen H, Queyrel V, et al. Wegener's granulomatosis in the elderly patient [in French]. Rev Med Interne 2001; 22: 12731.
  • 17
    Romas E, Murphy BF, d'Apice AJ, Kennedy JT, Niall JF. Wegener's granulomatosis: clinical features and prognosis in 37 patients. Aust N Z J Med 1993; 23: 16875.
  • 18
    Aasarod K, Iversen BM, Hammerström J, Bostad L, Vatten L, Jorstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 6118.
  • 19
    Luqmani RA, Bacon PA, Beaman M, Scott DG, Emery P, Lee SJ, et al. Classical versus non-renal Wegener's granulomatosis. QJM 1994; 87: 1617.
  • 20
    Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, et al. Wegener's granuloma: a series of 265 British cases seen between 1975 and 1985: a report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992; 83: 42738.
  • 21
    Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology (Oxford) 2001; 40: 4928.
  • 22
    Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 218798.
  • 23
    Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 11017.
  • 24
    Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 6718.
  • 25
    de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55: 318.
  • 26
    Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 27
    Cox DR. Regression models and life table tables. J R Stat Soc 1972; 34: 187219.
  • 28
    Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996; 101: 12934.
  • 29
    Lê Thi Huong Du, Wechsler B, Piette JC, de Gennes C, Cabane J, Blétry O, et al. Wegener's granulomatosis in elderly subjects: 37 cases [in French]. Presse Med 1988; 17: 237982.
  • 30
    Carrington CB, Liebow A. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1966; 41: 497527.
  • 31
    Daverat P, Castel JP, Dartigues JF, Orgogozo JM. Death and functional outcome after spontaneous intracerebral hemorrhage: a prospective study of 166 cases using multivariate analysis. Stroke 1991; 22: 16.
  • 32
    Koldingsnes W, Nossent H. A population based study of outcome in Wegener's granulomatosis. Presented at the 9th International ANCA Workshop; 2000 April 12–15; Groningen, Netherlands.
  • 33
    Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958; 2: 26570.
  • 34
    Godman GC, Churg J. Wegener's granulomatosis: pathology and review of the literature. Arch Pathol 1954; 58: 53353.
  • 35
    Bacon PA. Vasculitis from the rheumatologist's viewpoint. In: GrossWL, editor. ANCA-associated vasculitides: immunodiagnostic and pathogenetic roles of antineutrophil cytoplasmic autoantibodies. New York: Plenum Publishing; 1993. p. 18595.
  • 36
    Balding CE, Howie AJ, Drake-Lee AB, Savage CO. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001; 125: 3329.
  • 37
    Csernok E, Trabandt A, Muller A, Wang GC, Moosig F, Paulsen J, et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999; 42: 74250.
  • 38
    Muller A, Trabandt A, Gloeckner-Hofmann K, Seitzer U, Csernok E, Schonermarck U, et al. Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J Pathol 2000; 192: 11320.
  • 39
    Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 114954.
  • 40
    Jayne D, Rasmussen N. European collaborative trials in vasculitis: EUVAS-update and latest results. Presented at the 9th International ANCA Workshop; 2000 April 12–15; Groningen, Netherlands.
  • 41
    Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 266673.
  • 42
    Jayne D, Gaskin G, for the European Vasculitis Study Group (EUVAS). Randomized trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis. Presented at the 9th International ANCA Workshop; 2000 April 12–15; Groningen, Netherlands.